LENSAR Inc Ordinary Shares LNSR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LNSR is a good fit for your portfolio.
News
-
LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
-
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
-
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
LENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024
Trading Information
- Previous Close Price
- $3.12
- Day Range
- $3.18–3.38
- 52-Week Range
- $1.80–5.30
- Bid/Ask
- $3.02 / $3.37
- Market Cap
- $37.15 Mil
- Volume/Avg
- 15,145 / 43,480
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.85
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency and reproducibility by providing imaging, simplified procedure planning, efficient design and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The consumable portion of the system consists of a disposable patient interface device, or PID, kit and a procedure license. Each procedure on each system requires the use of a PID kit.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 130
- Website
- https://www.lensar.com
Valuation
|
Metric
|
LNSR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.10 |
Price/Sales | 0.85 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LNSR
|
|---|---|
Quick Ratio | 2.44 |
Current Ratio | 3.99 |
Interest Coverage | — |
Quick Ratio
LNSR
Profitability
|
Metric
|
LNSR
|
|---|---|
Return on Assets (Normalized) | −9.26% |
Return on Equity (Normalized) | −16.09% |
Return on Invested Capital (Normalized) | −15.04% |
Return on Assets
LNSR
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Fdplrlsbd | Lfjhhg | $184.2 Bil | |
SYK
| Stryker Corp | Wgxltrdr | Kvwcq | $125.1 Bil | |
MDT
| Medtronic PLC | Lwjfnrzm | Fjmhdk | $108.5 Bil | |
BSX
| Boston Scientific Corp | Kbfbljh | Fvcfvl | $107.1 Bil | |
EW
| Edwards Lifesciences Corp | Btzmsryq | Kssrsl | $51.4 Bil | |
DXCM
| DexCom Inc | Rzdttpbblf | Cyvdr | $50.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Hbbtpmkd | Yrvsv | $25.0 Bil | |
PHG
| Koninklijke Philips NV ADR | Svwnzgh | Glspwk | $24.4 Bil | |
ALGN
| Align Technology Inc | Cqwcmflc | Schxbk | $21.7 Bil | |
PODD
| Insulet Corp | Pwdwbwwr | Vlvvjl | $12.2 Bil |